First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222
This study is recruiting at 13 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- HNSCC
- SCLC
- NSCLC
- TNBC - Triple-Negative Breast Cancer
- CRC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Gilead Sciences
- Last updated on ClinicalTrials.gov
- September 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Florida · 1
- University of Miami · Miami, FL
Massachusetts · 2
- Dana Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
Missouri · 1
- Washington University · St Louis, MO
New York · 1
- Mount Sinai · New York, NY
Ohio · 2
- Cleveland Clinic · Cleveland, OH
- Ohio State University · Columbus, OH
Texas · 3
- NEXT Oncology Austin · Austin, TX
- NEXT Oncology - Dallas · Irving, TX
- NEXT Oncology - San Antonio · San Antonio, TX
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.